Valuation, from the filing
| Public float | $534.00M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-09-30 |
|---|---|---|
| Float per share | $0.50 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 11.9× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 3.6× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 5.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-09-30, not today, and each multiple below it uses the figures for the fiscal year ending 2026-03-31 — the year that filing covered.
Valuation over time
11.9× earnings today, against a median of 11.2× across 6 years on record. In line with its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-09-30 | $534.00M | 11.9× | |
| 2023-09-30 | $95.11M | 4.7× | |
| 2022-09-30 | $40.56M | 11.4× | |
| 2021-09-30 | $40.46M | 4.5× | |
| 2020-09-30 | $56.14M | 11.0× | |
| 2016-09-30 | $157.27M | 41.3× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Operating margin | 33.0% | 96th | |
| R&D / revenue | 3.9% | 6th | |
| Net margin | 30.1% | 91th | |
| FCF margin | 15.3% | 83th | |
| Revenue YoY growth | 77.1% | 81th | |
| Gross margin | 50.4% | 29th | |
| CapEx / revenue | 0.6% | 33th | |
| Current ratio | 6.45x | 67th | |
| Effective tax rate | 21.0% | 63th |
ELITE PHARMACEUTICALS INC /NV/ (ELTP) reported revenue of $141.01M and net income of $56.67M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ELITE PHARMACEUTICALS INC /NV/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $141.01M |
| Cost of revenue | $79.71M |
| Gross profit | $61.31M |
| Operating income | $34.94M |
| Net income | $56.67M |
| Research & development | $6.10M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $65.10M |
| Income tax expense | $8.43M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | Unavailable |
| General & administrative | $17.74M |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | Unavailable |
| Total assets | $139.67M |
| Current assets | $114.49M |
| Total liabilities | $34.84M |
| Current liabilities | $30.44M |
| Total equity incl. NCI | $104.83M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $24.20M |
| Accounts receivable | $50.44M |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | $5.59M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $19.04M |
| Capital expenditures | $1.52M |
| Investing cash flow | -$1.52M |
| Financing cash flow | -$306.22K |
| Net change in cash | $17.22M |
| Stock-based compensation | Unavailable |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $1.17M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $17.53M |
| Gross margin | 43.5% |
| Operating margin | 24.8% |
| FCF margin | 12.4% |
| SBC / revenue | Unavailable |
| Current ratio | 3.76x |
| Revenue YoY growth | 33.7% |
| Net margin | 40.2% |
| R&D / revenue | 4.3% |
| CapEx / revenue | 1.1% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | 12.9% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ELTP in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.